Carol Gleason
About Carol Gleason
Carol Gleason is an Associate Director at Bristol-Myers Squibb with over 30 years of experience in biostatistics and toxicology research.
Professional Title and Role
Carol Gleason holds the title of Associate Director at Bristol-Myers Squibb. She brings her expertise in biostatistics to the company's Princeton, NJ, and Syracuse, NY, locations. In her current role, she is responsible for advancing the biostatistical aspects of drug discovery and development.
Educational Background
Carol Gleason earned her Master of Science (MS) in Statistics and Measurement from Syracuse University, where she studied from 1980 to 1982. Prior to that, she completed her Bachelor of Science (BS) in Math and Psychology at Wilkes University, attending from 1976 to 1980.
Career Experience in Biostatistics
With over 30 years of experience, Carol Gleason has provided support for both regulated and non-regulated research studies across various fields, including general toxicology, genetic toxicology, reproductive studies, and immunotoxicology. Her career has been marked by a deep involvement in the development and validation of analytical methods for pharmacokinetic and biomarker assays. From 1983 to 2016, she served as a Principal Biostatistician at Bristol-Myers Squibb. She also operated as a self-employed Research Biostatistician from 1990 to 2005.
Expertise in Analytical Method Development
Carol Gleason possesses extensive knowledge in developing and validating analytical methods for pharmacokinetic and biomarker assays. Her expertise includes consulting with scientists to create 'fit-for-purpose' biomarker assays crucial for drug discovery and early drug development studies. Her role often involves working closely with scientists to ensure the assays meet the necessary standards for scientific research.
Focus on Drug Discovery and Development
Since taking on her current role in July 2017, Carol Gleason has expanded her support to include Lead Discovery. Her career is centered on fostering collaboration with scientists in drug development and drug discovery, optimizing biostatistical methodologies to enhance research outcomes.